Morningstar14d
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release ...
Business Wire16d
ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update
“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...
FoodNavigator17d
Is this GLP-1.2? New generation of weight-loss drugs moving in
CagriSema: Activating amylin and GLP-1 receptors CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials testing whether it can be ...
Insider Monkey17d
20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years
The company has grown its revenue by 18.58% over the last 5 years. NVO’s stock price fell after the CagriSema drug’s disappointing trial results. Despite strong earnings in the previous ...
Morningstar17d
Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug – Hagens Berman
Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...
abc2718d
A Securities Fraud Lawsuit Has Been Filed Against Novo Nordisk A/S And Investors With Losses Are Urged To Contact The Schall Law Firm
Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...
KELOLAND News20d
A Lawsuit Has Been Filed Against Novo Nordisk A/S For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...
The Boston Globe21d
Weight-loss drugs are about to get a lot better
The next generation of weight-loss drugs aim to help patients lose more weight even faster. CagriSema — developed by Novo Nordisk, the company behind Wegovy — is one example. In a trial last ...
Yahoo Finance21d
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...
The Victoria Advocate24d
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial, which determined that the Company's CagriSema product had achieved a weight loss average of only 22.7% after 68 weeks.
WOOD-TV24d
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...